We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
-3.39%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$2.6B
AUM Growth
+$272M
Cap. Flow
+$580M
Cap. Flow %
22.28%
Top 10 Hldgs %
59.11%
Holding
341
New
89
Increased
83
Reduced
62
Closed
85

Top Buys

Rank Stock Value
1
ACHC icon
Acadia Healthcare
ACHC
+$32.4M
2
AZN icon
AstraZeneca
AZN
+$11.6M
3
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$10.4M
4
QRHC icon
Quest Resource Holding
QRHC
+$8.96M
5
MBOT icon
Microbot Medical
MBOT
+$7.86M

Top Sells

Rank Stock Value
1
WY icon
Weyerhaeuser
WY
+$64.6M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$53.7M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$16.1M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$13.3M
5
OPK icon
Opko Health
OPK
+$10.5M

Sector Composition

Rank Sector Weight
1 Miscellaneous 92.32%
2 Healthcare 6.56%
3 Energy 0.47%
4 Consumer Discretionary 0.36%
5 Industrials 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACAD icon
251
CALL
Acadia Pharmaceuticals
ACAD
$4.61B
– –
-27,474
Closed -$62.1M
ACAD icon
252
Acadia Pharmaceuticals
ACAD
$4.61B
– –
-589,264
Closed -$13.3M
ACAD icon
253
PUT
Acadia Pharmaceuticals
ACAD
$4.61B
– –
-960
Closed -$2.17M
ACHV icon
254
CALL
Achieve Life Sciences
ACHV
$753M
– –
0
– -$164K
AGEN
255
PUT
Agenus
AGEN
$322M
– –
-12
Closed -$79K
ALNY icon
256
Alnylam Pharmaceuticals
ALNY
$31.9B
– –
-12,000
Closed -$774K
AMGN icon
257
Amgen
AMGN
$203B
– –
-49,703
Closed -$6.49M
AMRN
258
CALL
Amarin Corp
AMRN
$294M
– –
-270
Closed -$950K
AMRN
259
Amarin Corp
AMRN
$294M
– –
-32,500
Closed -$1.14M
ARWR icon
260
CALL
Arrowhead Research
ARWR
$9.98B
– –
-708
Closed -$1.01M
ASRT
261
CALL
DELISTED
Assertio
ASRT
– –
-9
Closed -$766K
BCRX icon
262
BioCryst Pharmaceuticals
BCRX
$2.09B
– –
-77,987
Closed -$994K
BLRX
263
BioLineRX
BLRX
$12.2M
– –
-3,369
Closed -$4.2M
BMY icon
264
Bristol-Myers Squibb
BMY
$130B
– –
-29,949
Closed -$1.5M
CGEN icon
265
CALL
Compugen
CGEN
$228M
– –
-150
Closed -$135K
ELV icon
266
CALL
Elevance Health
ELV
$90.6B
– –
-552
Closed -$5.94M
FOLD
267
DELISTED
Amicus Therapeutics
FOLD
– –
-100,000
Closed -$334K
EOCN
268
Eocene Ltd. Ordinary Shares
EOCN
$3.88M
– –
-22
Closed -$306K
INSM icon
269
CALL
Insmed
INSM
$26.2B
– –
-438
Closed -$873K
LPCN icon
270
Lipocine
LPCN
$18.1M
– –
-24,512
Closed -$2.54M
MGNX icon
271
MacroGenics
MGNX
$257M
– –
-149,839
Closed -$3.26M
NKTR icon
272
Nektar Therapeutics
NKTR
$2.28B
– –
-3,368
Closed -$648K
NVAX icon
273
Novavax
NVAX
$1.52B
– –
-20,919
Closed -$1.93M
NVAX icon
274
PUT
Novavax
NVAX
$1.52B
– –
-272
Closed -$2.52M
NVO
275
PUT
Novo Nordisk
NVO
$188B
– –
-848
Closed -$1.96M
9 10
11
12 13

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q3 2014 Portfolio in Review

As of Q3 2014, Sabby Management held 341 positions worth $2.6B, up 12% from $2.33B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Sabby Management deployed $580M of net new capital in Q3 2014, opening 89 new positions and adding to 83 existing holdings. Its largest new stake was Acadia Healthcare: 663,324 shares worth $16.4M.

By sector, the portfolio is most concentrated in Miscellaneous at 92% of assets, up from 87% a quarter earlier, followed by Healthcare and Energy.

On the sell side, the largest reduction was SALIX PHARMACEUTICALS LTD DEL, an estimated $6.87M trimmed.

  • Sabby Management's largest Q3 2014 buy was Acadia Healthcare: 663,324 shares worth $16.4M.
  • Sabby Management added most to AstraZeneca in Q3 2014, an estimated $11.6M increase.
  • Sabby Management's biggest Q3 2014 reduction was SALIX PHARMACEUTICALS LTD DEL, cutting an estimated $6.87M.
  • Sabby Management fully exited Weyerhaeuser in Q3 2014, selling an estimated $64.6M.
  • Sabby Management's ten largest holdings make up 59% of its $2.6B portfolio in Q3 2014.
  • Sabby Management opened 89 new positions and closed 85 in Q3 2014.
  • Sabby Management's portfolio value rose 12% quarter-over-quarter to $2.6B.

Based on Sabby Management's 13F filing for Q3 2014, filed 14 Nov 2014.